Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimal Duration of Antiplatelet Therapy After Bioresorbable Vascular Scaffold Implantation to Reduce Late Coronary Arterial Thrombotic Events: BVS-LATE Trial

NCT02939872 is registered in ClinicalTrials.gov with Seung-Jung Park as lead sponsor.

NCT NCT02939872
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02939872 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimal Duration of Antiplatelet Therapy After Bioresorbable Vascular Scaffold Implantation to Reduce Late Coronary Arterial Thrombotic Events: BVS-LATE Trial
Lead sponsor
Seung-Jung Park
Phase
Phase 4
Overall status
Completed
Start date
March 9, 2017
Completion date
June 3, 2024
Enrollment
238 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

coronary disease, percutaneous transluminal coronary angioplasty